(RCUS) Arcus Biosciences - Ratings and Ratios
HIF-2a-Inhibitor, Anti-TIGIT-Antibody, CD73-Inhibitor, Adenosine-Antagonist, Anti-PD-1, CD39-Antibody
EPS (Earnings per Share)
Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 62.6% |
| Value at Risk 5%th | 93.0% |
| Relative Tail Risk | -9.75% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.86 |
| Alpha | 32.03 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.402 |
| Beta | 1.346 |
| Beta Downside | 1.040 |
| Drawdowns 3y | |
|---|---|
| Max DD | 80.76% |
| Mean DD | 55.03% |
| Median DD | 54.16% |
Description: RCUS Arcus Biosciences November 17, 2025
Arcus Biosciences (NYSE:RCUS) is a clinical-stage biopharma focused on oncology immunotherapies in the United States. Its lead assets include Casdatifan (a HIF-2α inhibitor for renal cell carcinoma) and Domvanalimab (an anti-TIGIT antibody currently in Phase 2/3 trials for lung and gastrointestinal cancers). The pipeline also contains Quemliclustat (CD73 inhibitor in Phase 3 for lung cancer and Phase 1/1b for pancreatic cancer), Etrumadenant (dual A2a/A2b adenosine-receptor antagonist in Phase 2 for colorectal cancer), Zimberelimab (anti-PD-1), AB598 (CD39 antibody in Phase 1/1b for GI cancers) and AB801 (AXL inhibitor in Phase 1b for lung cancer). Arcus collaborates with AstraZeneca on the Phase 3 PACIFIC-8 trial (Domvanalimab + Durvalumab in Stage 3 NSCLC) and on a Phase 1/1b study of Casdatifan + Volrustomig in treatment-naïve clear-cell RCC, and partners with BVF Partners for inflammatory-disease programs.
As of the latest 10-Q (Q3 2024), Arcus reported cash and cash equivalents of roughly $210 million, giving it an estimated 18-month runway at current burn rates. The company’s market capitalization sits near $1.2 billion, reflecting a modest premium to peers despite the early-stage nature of its assets. Industry-wide, immuno-oncology R&D spend grew ~9 % YoY in 2023, and the global HIF-2α inhibitor market is projected to exceed $1 billion by 2028, providing a favorable macro backdrop for Casdatifan’s target indication.
If you want a deeper, data-driven look at Arcus’s valuation dynamics and how its pipeline risk-adjusted returns compare to sector averages, the ValueRay platform offers a transparent, model-backed analysis worth exploring.
RCUS Stock Overview
| Market Cap in USD | 2,473m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2018-03-15 |
| Return 12m vs S&P 500 | 29.8% |
| Analyst Rating | 4.46 of 5 |
RCUS Dividends
Currently no dividends paidRCUS Growth Ratios
| Metric | Value |
|---|---|
| CAGR 3y | -7.43% |
| CAGR/Max DD Calmar Ratio | -0.09 |
| CAGR/Mean DD Pain Ratio | -0.14 |
| Current Volume | 2127.7k |
| Average Volume | 1450.2k |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-349.0m TTM) > 0 and > 6% of Revenue (6% = 14.4m TTM) |
| FCFTA -0.48 (>2.0%) and ΔFCFTA -34.14pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 259.2% (prev 346.8%; Δ -87.60pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.47 (>3.0%) and CFO -462.0m <= Net Income -349.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.65 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (106.5m) change vs 12m ago 16.52% (target <= -2.0% for YES) |
| Gross Margin 97.08% (prev 96.20%; Δ 0.89pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 21.56% (prev 21.01%; Δ 0.56pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -41.62 (EBITDA TTM -323.0m / Interest Expense TTM 8.00m) >= 6 (WARN >= 3) |
Altman Z'' -1.59
| (A) 0.64 = (Total Current Assets 857.0m - Total Current Liabilities 235.0m) / Total Assets 974.0m |
| (B) -1.42 = Retained Earnings (Balance) -1.38b / Total Assets 974.0m |
| warn (B) unusual magnitude: -1.42 — check mapping/units |
| (C) -0.30 = EBIT TTM -333.0m / Avg Total Assets 1.11b |
| (D) 0.81 = Book Value of Equity 436.0m / Total Liabilities 538.0m |
| Total Rating: -1.59 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 34.00
| 1. Piotroski 1.50pt |
| 2. FCF Yield -26.46% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.25 |
| 5. Debt/Ebitda 0.39 |
| 6. ROIC - WACC (= -68.74)% |
| 7. RoE -69.77% |
| 8. Rev. Trend 24.59% |
| 9. EPS Trend 16.08% |
What is the price of RCUS shares?
Over the past week, the price has changed by +7.28%, over one month by +21.52%, over three months by +110.41% and over the past year by +45.21%.
Is RCUS a buy, sell or hold?
- Strong Buy: 8
- Buy: 3
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the RCUS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 32 | 50.7% |
| Analysts Target Price | 32 | 50.7% |
| ValueRay Target Price | 23.1 | 8.9% |
RCUS Fundamental Data Overview November 19, 2025
P/S = 10.3056
P/B = 5.6955
Beta = 0.777
Revenue TTM = 240.0m USD
EBIT TTM = -333.0m USD
EBITDA TTM = -323.0m USD
Long Term Debt = 98.0m USD (from longTermDebt, last quarter)
Short Term Debt = 13.0m USD (from shortTermDebt, last quarter)
Debt = 111.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -127.0m USD (from netDebt column, last quarter)
Enterprise Value = 1.75b USD (2.47b + Debt 111.0m - CCE 831.0m)
Interest Coverage Ratio = -41.62 (Ebit TTM -333.0m / Interest Expense TTM 8.00m)
FCF Yield = -26.46% (FCF TTM -464.0m / Enterprise Value 1.75b)
FCF Margin = -193.3% (FCF TTM -464.0m / Revenue TTM 240.0m)
Net Margin = -145.4% (Net Income TTM -349.0m / Revenue TTM 240.0m)
Gross Margin = 97.08% ((Revenue TTM 240.0m - Cost of Revenue TTM 7.00m) / Revenue TTM)
Gross Margin QoQ = 92.31% (prev 98.75%)
Tobins Q-Ratio = 1.80 (Enterprise Value 1.75b / Total Assets 974.0m)
Interest Expense / Debt = 2.70% (Interest Expense 3.00m / Debt 111.0m)
Taxrate = -0.0% (0.0 / -135.0m)
NOPAT = -333.0m (EBIT -333.0m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 3.65 (Total Current Assets 857.0m / Total Current Liabilities 235.0m)
Debt / Equity = 0.25 (Debt 111.0m / totalStockholderEquity, last quarter 436.0m)
Debt / EBITDA = 0.39 (negative EBITDA) (Net Debt -127.0m / EBITDA -323.0m)
Debt / FCF = 0.27 (negative FCF - burning cash) (Net Debt -127.0m / FCF TTM -464.0m)
Total Stockholder Equity = 500.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -35.83% (Net Income -349.0m / Total Assets 974.0m)
RoE = -69.77% (Net Income TTM -349.0m / Total Stockholder Equity 500.2m)
RoCE = -55.66% (EBIT -333.0m / Capital Employed (Equity 500.2m + L.T.Debt 98.0m))
RoIC = -58.12% (negative operating profit) (NOPAT -333.0m / Invested Capital 573.0m)
WACC = 10.62% (E(2.47b)/V(2.58b) * Re(10.98%) + D(111.0m)/V(2.58b) * Rd(2.70%) * (1-Tc(-0.0)))
Discount Rate = 10.98% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 19.16%
Fair Price DCF = unknown (Cash Flow -464.0m)
EPS Correlation: 16.08 | EPS CAGR: -41.25% | SUE: 0.02 | # QB: 0
Revenue Correlation: 24.59 | Revenue CAGR: -8.96% | SUE: 0.11 | # QB: 0
Additional Sources for RCUS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle